Mr. Frank Gleeson reports

SATELLOS TO HOST INVESTOR CALL TO PROVIDE AN UPDATE ON CLINICAL AND REGULATORY STRATEGY FOR THE BASECAMP PHASE 2 PEDIATRIC STUDY

Satellos Bioscience Inc. will host a conference call and audio webcast at 8 a.m. ET on Friday, Nov. 6, 2026, to provide an update on the clinical and regulatory strategy for Basecamp, the company's phase 2 pediatric study in boys seven, eight or nine years old with Duchenne muscular dystrophy (DMD). The call will feature remarks from Satellos co-founder and chief executive officer Frank Gleeson and chief medical officer Dr. Wildon Farwell, MD.

A live webcast of the conference call and accompanying slides will be available on the events and presentations page of the investors section of the company's website. A replay will be available following the presentation.

Conference call details

Domestic:   1-877-269-7751

International:  1-201-389-0908

About Satellos Bioscience Inc.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small-molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment for DMD in two phase 2 clinical trials, Basecamp in pediatric participants with DMD and Trailhead in adults living with DMD. An investigational new drug (IND) application to initiate clinical research into forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD) has also been cleared. The company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development.

We seek Safe Harbor.